SynAct Pharma AB (SYNACT.ST)
SEK 19.6
(-1.31%)
SEK 19.6
(-1.31%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -6.64 SEK | -84.44% |
| 2022 | -3.60 SEK | -34.83% |
| 2021 | -2.67 SEK | -117.07% |
| 2020 | -1.23 SEK | 24.07% |
| 2019 | -1.62 SEK | 4.71% |
| 2018 | -1.70 SEK | -37.1% |
| 2017 | -1.24 SEK | 4.62% |
| 2016 | -1.30 SEK | -828.57% |
| 2015 | -0.14 SEK | -7.69% |
| 2014 | -0.13 SEK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.70 SEK | 72.87% |
| 2024 Q2 | -0.47 SEK | 32.86% |
| 2024 Q3 | -0.50 SEK | -6.38% |
| 2023 Q2 | -1.37 SEK | 13.84% |
| 2023 Q4 | -2.58 SEK | -158.0% |
| 2023 Q3 | -1.00 SEK | 27.01% |
| 2023 FY | - SEK | -84.44% |
| 2023 Q1 | -1.59 SEK | -50.0% |
| 2022 Q2 | -0.91 SEK | -18.18% |
| 2022 Q4 | -1.06 SEK | -26.19% |
| 2022 FY | - SEK | -34.83% |
| 2022 Q1 | -0.77 SEK | 23.76% |
| 2022 Q3 | -0.84 SEK | 7.69% |
| 2021 Q4 | -1.01 SEK | -44.29% |
| 2021 FY | - SEK | -117.07% |
| 2021 Q3 | -0.70 SEK | -37.25% |
| 2021 Q2 | -0.51 SEK | -10.87% |
| 2021 Q1 | -0.46 SEK | -27.78% |
| 2020 Q3 | -0.31 SEK | 8.82% |
| 2020 Q4 | -0.36 SEK | -16.13% |
| 2020 FY | - SEK | 24.07% |
| 2020 Q1 | -0.25 SEK | 53.7% |
| 2020 Q2 | -0.34 SEK | -36.0% |
| 2019 Q2 | -0.43 SEK | -59.26% |
| 2019 Q4 | -0.54 SEK | -157.14% |
| 2019 FY | - SEK | 4.71% |
| 2019 Q1 | -0.27 SEK | 34.15% |
| 2019 Q3 | -0.21 SEK | 51.16% |
| 2018 Q3 | -0.45 SEK | 15.09% |
| 2018 Q4 | -0.41 SEK | 8.89% |
| 2018 FY | - SEK | -37.1% |
| 2018 Q2 | -0.53 SEK | -112.0% |
| 2018 Q1 | -0.25 SEK | 45.65% |
| 2017 FY | - SEK | 4.62% |
| 2017 Q1 | -0.27 SEK | 55.74% |
| 2017 Q4 | -0.46 SEK | -206.67% |
| 2017 Q3 | -0.15 SEK | 54.55% |
| 2017 Q2 | -0.33 SEK | -22.22% |
| 2016 Q2 | -0.43 SEK | 0.0% |
| 2016 Q3 | -0.16 SEK | 62.79% |
| 2016 Q4 | -0.61 SEK | -281.25% |
| 2016 FY | - SEK | -828.57% |
| 2015 FY | - SEK | -7.69% |
| 2014 FY | - SEK | 0.0% |